Welcome address by Natalia Baeva, Director of the Global Pharmaceutical Leaders' Club
Mikheil Sarjveladze, Minister of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia to be confirmed
"Global trends in pharmaceutical market development and their adaptation in Central Asia, the Caucasus, Eastern and Central Europe"
"Accelerating access to innovative therapies: what needs to change today?"
"Quality matters: generics as a strategic resource for healthcare"
"From patient needs to solutions: how to improve access to medicines"
Value creation for industry, improving decision-making, barriers limiting adoption across countries, regulatory adaptations to drug development/pharmacovigilance, necessary skills.
International experience and best practices, clinical value metrics, supply chain resilience, avoiding medicine shortages, modern therapeutics access, digitalization.
Comparison of state pricing models, impact on patient access, shortage risks, reduced attractiveness under strict controls, reference pricing, harmonisation.
Transition from reactive to proactive risk management, real-world clinical practice data usage, AI-powered safety signals, multi-stakeholder collaboration.
Case study analysis and solution development: mapping out the future look of the pharmaceutical industry under the disruptive influence of AI.
"From warehouse to patient": model transformation, supply chain resilience, e-commerce adoption, price regulation economics, consumer expectations, market consolidation.
Global study designs, accelerating processes, regulatory impact on quality, building infrastructure for international sponsors, Georgia's emerging role as exchange hub.
Balancing access, quality, and traceability; structural impact on competition and supply chain stability.
Adapting regulatory systems to accelerated development, mutual recognition procedures, and electronic dossiers.
Balancing import substitution and global integration, investment incentives, technology transfer, and supply chains.
Ensuring access to rare therapies under constrained budgets, reimbursement models, and role of patient groups.
Sessions with regulatory bodies of Türkiye, Central Asian countries, Caucasus, Mongolia, Moldova, Belarus, and Eastern/Central Europe. *Timings to be confirmed by authorities.
Interactive masterclasses focused on driving and managing digital transformation strategies across pharma.
IP role in stimulating pharmaceutical innovation, patent protection vs access, impact on local manufacturing, competition, and generic launches.
Criteria for inclusion (efficacy, safety, pharmacoeconomics), health technology assessment (HTA) role, international approaches to adaptive review.
Sustainable and equitable therapy inclusion in reimbursement packages, insurance financial health amid rising costs, co-financing frameworks.
Transition from acute treatment to health management, dietary supplements/functional foods evidence base, safety regulation and market control.
One-on-one meetings with senior executives of distribution companies and major pharmacy chains.
Targeted meetings and consultations with various international regulatory delegations.
Visits to a pharmaceutical manufacturing plant / distribution warehouse / pharmacy chain to be confirmed
Lunch at a traditional Georgian restaurant
Stay informed via our Telegram channel — your source for news, updates, and key information.
Join the channel